At what prices did the ALHC CEO’s April 7, 2026 share sales occur?

The CEO’s reported sales occurred at weighted-average prices of $20.67 and $21.3953 per share. Footnotes explain that actual trades spanned price ranges from $20.18 to $21.17 and from $21.18 to $21.56 across multiple individual transactions.

Were the ALHC CEO’s share sales made under a Rule 10b5-1 trading plan?

Yes. A footnote states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on November 21, 2025. Such plans pre-schedule trades, helping separate routine portfolio management from discretionary market-timing decisions by insiders.

Alignment Healthcare (NASDAQ: ALHC) CEO sells 250K shares under 10b5-1 plan

Filing Impact

(Very High)

Filing Sentiment

(Very Negative)

Form Type

Rhea-AI Filing Summary

Alignment Healthcare, Inc. director and Chief Executive Officer John E. Kao reported open-market sales of a total of 250,000 shares of Common Stock on April 7, 2026, through indirect holdings. The sales occurred at weighted-average prices of $20.67 and $21.3953 per share.

The indirectly held shares are owned by the JEK Trust, dated February 8, 2021, for which Mr. Kao serves as trustee. After these transactions, he continues to hold 2,104,641 shares indirectly and 1,784,868 shares directly. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on November 21, 2025.

Insider Trade Summary 10b5-1

Net Seller: 250,000 shares ($5,252,911)

Net Sell 3 txns

Insider KAO JOHN E

Role Chief Executive Officer

Sold 250,000 shs ($5.25M)

Type	Security	Shares	Price	Value
Sale	Common Stock	132,241	$20.67	$2.73M
Sale	Common Stock	117,759	$21.3953	$2.52M
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 2,222,400 shares (Indirect, See Footnote); Common Stock — 1,784,868 shares (Direct)

Footnotes (1)

Date of Rule 10b5-1 plan adoption: 11/21/2025 The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $20.18 to $21.17. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $21.18 to $21.56. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

Key Figures

Shares sold: 250,000 shares First sale price: $20.67 per share Second sale price: $21.3953 per share +3 more

6 metrics

Shares sold 250,000 shares Total Common Stock sold in open market on April 7, 2026

First sale price $20.67 per share Weighted-average price for 132,241 shares sold

Second sale price $21.3953 per share Weighted-average price for 117,759 shares sold

Indirect holdings after trades 2,104,641 shares Common Stock held indirectly via JEK Trust after sales

Direct holdings 1,784,868 shares Common Stock held directly after reported transactions

Rule 10b5-1 plan adoption date November 21, 2025 Plan governing pre-scheduled insider trades

Key Terms

Rule 10b5-1 plan, weighted-average price, open-market sale, indirect ownership, +1 more

5 terms

Rule 10b5-1 plan regulatory

"Date of Rule 10b5-1 plan adoption: 11/21/2025"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted-average price financial

"The reported price in column 4 is a weighted-average price."

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

"direct_or_indirect": "I","nature_of_ownership": "See Footnote""

JEK Trust financial

"Represents securities held by JEK Trust, dated February 8, 2021"

Form 4 Insider Transactions: What Each Field Means →

04/08/2026 - 05:48 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KAO JOHN E

(Last)

(First)

(Middle)

1100 W. TOWN & COUNTRY RD., SUITE 1600

(Street)

ORANGE

CALIFORNIA

92868

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/07/2026		S⁽¹⁾		132,241	D	$20.67⁽²⁾	2,222,400	I	See Footnote⁽³⁾
Common Stock	04/07/2026		S⁽¹⁾		117,759	D	$21.3953⁽⁴⁾	2,104,641	I	See Footnote⁽³⁾
Common Stock								1,784,868	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Date of Rule 10b5-1 plan adoption: 11/21/2025

2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $20.18 to $21.17. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

3. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

4. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $21.18 to $21.56. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

Remarks:

	/s/ Christopher J. Joyce, as Attorney-in-Fact, for John E. Kao	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Alignment Healthcare (ALHC) CEO John E. Kao report in this Form 4?

John E. Kao reported selling 250,000 shares of Alignment Healthcare Common Stock in open-market transactions. The sales were executed through indirect holdings and disclosed as part of his insider ownership reporting obligations for transparency with shareholders and regulators.

How many Alignment Healthcare (ALHC) shares does John E. Kao hold after these transactions?

After the reported sales, John E. Kao holds 2,104,641 shares of Alignment Healthcare Common Stock indirectly and 1,784,868 shares directly. These figures show he retains a substantial ownership position in the company following the 250,000-share disposition.

How are the ALHC shares sold by the CEO held, and what is the JEK Trust?

The sold shares are held indirectly through the JEK Trust, dated February 8, 2021. A footnote explains that the securities are owned by this trust, with John E. Kao serving as trustee, so the Form 4 attributes these holdings to him for reporting purposes.

Does this ALHC Form 4 include any derivative security exercises or only common stock sales?

This Form 4 reports only non-derivative Common Stock transactions, specifically open-market sales. The derivativeSummary section is empty and transaction details do not show any option exercises, conversions, or other derivative-related activity associated with these trades.